Hikma now expects 20% sales growth; Mylan to pay $250K fine in EpiPen ad case;

@FiercePharma: Best-read story this morning: Top 10 Drug Patent Losses for 2014. More | Follow @FiercePharma

@CarlyHFierce:  EU watchdogs demand info on AstraZeneca's disputed Brilinta trial. More | Follow @CarlyHFierce

> Jordan-based Hikma Pharmceuticals raised its sales forecast to reflect revenue growth of 20% and hiked its generics expectations on soaring sales of its antibiotic doxycycline. Report

> A Mylan ($MYL) subsidiary agreed to pay $250,000 to the state of Oregon and submit future TV commercials for review after allegations that its EpiPen advertising was misleading. Report

> The board of South Africa's Adcock Ingram continues to back a buyout bid from Chile's CFR Pharmaceuticals despite opposition from its biggest shareholder. Report

> India's drug regulator asked Sun Pharmaceuticals to halt clinical research at a Mumbai laboratory, saying the facility had not been approved. Report

> Polio may return to Europe as regional conflicts interfere with eradication efforts; the disease returned to war-torn Syria last month after a 14-year absence. Report

Medical Device News

@FierceMedDev: ICYMI: OrthoSensor links with Zimmer to sell knee replacement-balancing tech. Story | Follow @FierceMedDev

@MarkHFierce: Foundation Medicine's first quarterly earnings as a public company reflect impressive growth. Article | Follow @MarkHFierce

@MichaelGFierce: From FierceDrugDelivery this week: Novo Nordisk wins FDA approval for two automated-dose insulin pens. More | Follow @MichaelGFierce

> Chinese investors pursue groundbreaking med tech from Canada's MDI. News

> A pharma-free Covidien achieves moderate medical device growth. More

> Sequestration takes its toll on FDA user fees paid by industry. Item

Biotech News

@FierceBiotech: Teva fills CFO position as Desheh steps up to CEO, plus more of this week's career moves in biopharma. News | Follow @FierceBiotech

@JohnCFierce: FDA bottom line: unless there's a fantastic benefit, don't approve Lemtrada. Sanofi shares slip. | Follow @JohnCFierce

@DamianFierce: Updated Ariad job-cut story: EMA committee says Iclusig OK for now; stronger label on the way. More | Follow @DamianFierce

@EmilyMFierce: ICYMI: Report proposes revamping Alzheimer's R&D. Story | Follow @EmilyMFierce

> J&J innovation team sets up international collaboration to discover Alzheimer's drugs. Story

> Bristol-Myers axing up to 75 R&D staffers, halts discovery work in three fields. Article

> Sangart goes MIA after burning through $260M-plus on R&D. News

> FDA casts 'fatal' doubts on Sanofi's long-stalled MS drug Lemtrada. More

And Finally... The Obama administration is issuing rules defining equal treatment insurance coverage of mental illness and addiction. Report (sub. req.)

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.